Katherine Watt interviewed: https://www.bitchute.com/video/zdct156R26y5/ , try from 19:52 and from 25:35 on how Congress subverted the Constitution on countermeasures, perferring some kind of stealth dictatorship.
At 31:05: the controllers “need abosolute control of the information” to keep fear levels high and the public in the dark. “Information control is the top of the control pyramid” to distort all else In foreign contracts big pharma stipulated that “no third party independent testing can be done” but obviously the contracting governments could all along have tested the vials.
……………….....................
At 0:47 of https://www.bitchute.com/video/FA6w6QJ75aYH/ the guy says “at year 2000 in leaked speech the CCP defense minister advocated using bioweapon to take out 100-200 million Americans and colonize America for farmland”.
……………………......................
Naomi Wolf says “Wuxi Biologic manufactures the lipid nanoparticles that are in all these
mRNA injections”: and also bought a Pfizer plant in China: https://www.bitchute.com/video/yzbiDC7LNGPR/
……………….........................
SHANGHAI, September 9, 2022 – WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its Wuxi city campus. Created in response to the increasing demand for complex injection dosage forms, this new facility marks the company’s fast-growing parenteral formulation capabilities and is yet another opportunity to enable customers as they develop and deliver better medicines for patients.
This new facility integrates multi-channel chip, micro-mixer system, and complex preparation system into a multi-channel micro-mixer core LNP manufacturing platform, offering significant advantages in drug-loading, liposome particle size control, and encapsulation efficiency. In addition, the modular design provides greater processing flexibility, enabling this platform to serve a wide range of manufacturing scales from 10-50 L per batch.
…WuXi STA has 12 sites across the U.S., Europe and Asia that offer a wide range of services and meet global regulatory standards. Together with other development and manufacturing sites, this new platform provides considerable synergy with the company’s oligonucleotide CRDMO platform. The LNP delivery system is particularly advantageous in overcoming the bioavailability challenge of oligonucleotides and their conjugates.
Dr. Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA, commented, “We are pleased to support our partners with this state-of-the-art LNP facility to meet the growing demand for advanced injection dosage forms. We will continue to expand our CRDMO platform’s capacity and capabilities to enable our partners to accelerate more innovative drugs to market for patients worldwide.”
http://www.STApharma.com https://www.wuxiapptec.com/news/wuxi-news/5194
………….......................
The latest phase of WuXi's integrated biologics project in Shanghai, which kicked off early work in 2020, brings a drug substance facility and two drug product plants into the fold. (Pixabay)
After a busy stretch planting manufacturing flags in Europe and the U.S., WuXi Biologics is returning to its spree of Asia-focused expansions.
Monday the contract researcher, developer and manufacturer cut the ribbon on its integrated biologics center in the Fengxian District of Shanghai.
The new facility bolsters development and manufacturing capacity at WuXi's existing center, which now supports end-to-end services for biologics projects spanning process development, analytical development, drug product development and quality control, plus more, WuXi said in a release. Work on the 1.6 million-square-foot integrated biologics center kicked off back in November 2018. The initial phase of the center revved up operations in 2020, providing a range of services such as antibody generation, complex biologics discovery and bispecific and multispecific antibody identification.
The latest phase of the project brings a drug substance facility and two drug product plants into the fold, WuXi added. These facilities are intended to help meet demand for clinical materials “at various scales and volumes,” the contractor said.
WuXi Biologics' biologics center counts more than 1,000 employees among its workforce, 70% of whom have at least a master’s degree, the company pointed out.
WuXi is touting the completed project’s potential to deliver “any biologics project with unprecedented speed … from early discovery to commercial manufacturing—all within the Center.”
With a Delaware site code-named 'Project Dragonfly,' WuXi's STA plans to add 1,200 jobs in US expansion: reports
The campus has also been designed with the planet’s health in mind, WuXi noted. The site applies “green designs” like heat recovery and water recycling systems meant to shrink the site’s environmental footprint. Further, the company has started a rooftop solar power program that’s expected to slash carbon emissions by “hundreds of tons every year.”
The new site is the latest in a string of expansions for WuXi Biologics.
In July, the rising manufacturing star joined the slew of biopharma outfits setting up shop in Singapore, with plans to invest $1.4 billion over the next 10 years to beef up research and development, plus large-scale drug substance and drug product manufacturing in-country.
Bristol Myers offloading Swiss tablet and capsule plant to Chinese CDMO WuXi STA
About a year before that, WuXi Bio locked up a deal to acquire more than 90% of CMAB, a China-based CDMO whose services run the gamut from cell-line and process development through clinical manufacturing. The move was designed to net WuXi 7,000 liters more drug substance and drug product capacity for liquid and freeze-drying projects across its global manufacturing network.
Outside China, WuXi Biologics bookended 2020 with deals for a pair of Bayer facilities in Leverkusen and Wuppertal, Germany. That same year, the company also inked a 10-year lease agreement for a 66,000-square-foot clinical manufacturing facility in Cranbury, New Jersey, which followed a lease agreement in May for a 33,000-square-foot process development lab in King of Prussia, Pennsylvania. https://www.fiercepharma.com/manufacturing/busy-wuxi-biologics-debuts-three-new-manufacturing-facilities-integrated-biologics
………………................
.......
Wuxi apptec: appoints Dr. minzhang Chen as the co CEO
Aug 02, 2021 07:12 PM (GMT+8)
Wuxi apptec announced that the company plans to optimize its organizational structure and add a joint CEO. The board of directors of the company agrees to amend the articles of association of Wuxi; Wuxi apptec new drug development Co., Ltd. on the relevant terms set by the joint CEO, and agrees to appoint Dr. minzhang Chen (Chen minzhang) as the joint CEO on the premise that the above amendment of the articles of association is approved by the general meeting of shareholders of the company, The term of office starts from the date when the aforesaid amendment to the articles of association is deliberated and approved by the general meeting of shareholders and ends on the date when the term of office of the second board of directors of the company expires.
https://equalocean.com/briefing/20210802230065602
……….....................…
No comments:
Post a Comment